Cullen Frost Bankers Inc increased its stake in Workday Inc Cl A Com (WDAY) by 916.5% based on its latest 2018Q1 regulatory filing with the SEC. Cullen Frost Bankers Inc bought 53,212 shares as the company’s stock rose 2.34% while stock markets declined. The institutional investor held 59,018 shares of the technology company at the end of 2018Q1, valued at $7.50 million, up from 5,806 at the end of the previous reported quarter. Cullen Frost Bankers Inc who had been investing in Workday Inc Cl A Com for a number of months, seems to be bullish on the $27.57 billion market cap company. The stock decreased 0.04% or $0.05 during the last trading session, reaching $128.15. About 855,466 shares traded. Workday, Inc. (NYSE:WDAY) has risen 30.14% since June 15, 2017 and is uptrending. It has outperformed by 17.57% the S&P500. Some Historical WDAY News: 30/05/2018 – Workday Co-Founder and CEO Aneel Bhusri to Keynote at the Bank of America Merrill Lynch 2018 Global Technology Conference; 12/03/2018 – Michigan.gov: Highland Recreation Area – Volunteer Stewardship Workday; 16/04/2018 – Michigan.gov: Saugatuck Dunes State Park – Volunteer Stewardship Workday; 11/04/2018 – WORKDAY INC – ANNOUNCED IT IS EXPANDING ITS OPERATIONS INTO ITALY; 08/03/2018 – Workday Announces Annual Stockholder Meeting; 22/04/2018 – DJ Workday Inc Class A, Inst Holders, 1Q 2018 (WDAY); 26/04/2018 – Workday Ranks #1 Best Place to Work in the UK; 07/03/2018 DocuSign picks banks for potential IPO in April; 30/04/2018 – Fidelity Select Software Adds Box, Cuts Workday; 23/04/2018 – Michigan.gov: P.J. Hoffmaster State Park – Volunteer Stewardship Workday
Los Angeles Capital Management & Equity Research Inc increased its stake in Clovis Oncology Inc (CLVS) by 67.88% based on its latest 2018Q1 regulatory filing with the SEC. Los Angeles Capital Management & Equity Research Inc bought 14,485 shares as the company’s stock declined 12.39% with the market. The institutional investor held 35,824 shares of the health care company at the end of 2018Q1, valued at $1.89 million, up from 21,339 at the end of the previous reported quarter. Los Angeles Capital Management & Equity Research Inc who had been investing in Clovis Oncology Inc for a number of months, seems to be bullish on the $2.38B market cap company. The stock increased 0.69% or $0.31 during the last trading session, reaching $45.34. About 639,473 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 11.65% since June 15, 2017 and is downtrending. It has underperformed by 24.22% the S&P500. Some Historical CLVS News: 06/04/2018 – Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer; 10/04/2018 – CLOVIS ONCOLOGY: SEC ISSUED WELLS NOTICES ON APRIL 9; 03/04/2018 – Merck, AstraZeneca: Lynparza Would Be First PARP Inhibitor for Breast Cancer in Europe; 15/04/2018 – Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at; 23/03/2018 – CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets; 15/04/2018 – ASTRAZENECA, MERCK & CO.: LYNPARZA MEDIAN SURVIVAL 19.3 MONTHS; 29/05/2018 – CLOVIS SAYS EC AUTHORIZES RUBRACA FOR RECURRENT OVARIAN CANCER; 03/04/2018 – The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer; 08/05/2018 – LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer; 16/05/2018 – G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Investors sentiment is 1.05 in 2018 Q1. Its the same as in 2017Q4. It is without change, as 27 investors sold CLVS shares while 65 reduced holdings. only 27 funds opened positions while 70 raised stakes. 48.28 million shares or 1.64% less from 49.09 million shares in 2017Q4 were reported. Proshare Advisors Ltd Liability accumulated 30,254 shares or 0.01% of the stock. Emerald Advisers Incorporated Pa stated it has 0.44% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). The New York-based Ghost Tree Ltd Liability Co has invested 0.8% in Clovis Oncology, Inc. (NASDAQ:CLVS). Geode Capital Mngmt Ltd Company holds 0.01% or 446,397 shares in its portfolio. Lpl Financial Lc invested in 5,461 shares. Federated Investors Inc Pa has 8,300 shares. Principal Fincl Grp holds 64,437 shares. Argentiere Ag owns 60,000 shares. Hightower Advisors Limited Com holds 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 4,197 shares. State Board Of Administration Of Florida Retirement Systems holds 0% or 25,020 shares. Sector Gamma As holds 123,892 shares. Profund Ltd Llc owns 17,577 shares. New Jersey Better Educational Savings Tru reported 4,000 shares or 0.23% of all its holdings. Strs Ohio holds 2,500 shares. California State Teachers Retirement Sys reported 66,924 shares stake.
Since January 8, 2018, it had 0 buys, and 6 selling transactions for $1.45 million activity. SPICKSCHEN THORLEF sold $292,365 worth of stock.
Los Angeles Capital Management & Equity Research Inc, which manages about $15.74 billion and $17.65 billion US Long portfolio, decreased its stake in Arch Cap Group Ltd (NASDAQ:ACGL) by 69,624 shares to 94,976 shares, valued at $8.13 million in 2018Q1, according to the filing. It also reduced its holding in Brooks Automation In (NASDAQ:BRKS) by 19,995 shares in the quarter, leaving it with 8,811 shares, and cut its stake in F5 Networks Inc (NASDAQ:FFIV).
Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 65 analyst reports since September 10, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Monday, April 4 by Piper Jaffray. The firm has “Buy” rating given on Thursday, June 1 by J.P. Morgan. Leerink Swann maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Monday, February 5 with “Buy” rating. The firm has “Outperform” rating given on Thursday, February 22 by RBC Capital Markets. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Buy” rating by RBC Capital Markets on Sunday, June 10. The firm has “Overweight” rating by JP Morgan given on Wednesday, May 17. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Friday, September 23 by SunTrust. The stock has “Overweight” rating by PiperJaffray on Thursday, January 26. Janney Capital upgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Tuesday, June 20 to “Buy” rating. The rating was downgraded by JP Morgan to “Neutral” on Wednesday, April 13.
More important recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Seekingalpha.com which released: “Immunomedics: Short-Term Risk, Long-Term Opportunity” on June 13, 2018, also Nasdaq.com published article titled: “Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today”, Nasdaq.com published: “Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in …” on June 04, 2018. More interesting news about Clovis Oncology, Inc. (NASDAQ:CLVS) was released by: Seekingalpha.com and their article: “Applied Materials Has Been Overly Punished – Cramer’s Lightning Round (5/29/18)” with publication date: May 30, 2018.
Among 51 analysts covering Workday (NYSE:WDAY), 21 have Buy rating, 4 Sell and 26 Hold. Therefore 41% are positive. Workday had 207 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Friday, July 7. On Thursday, September 10 the stock rating was initiated by BTIG Research with “Buy”. The stock has “Outperform” rating by William Blair on Monday, August 24. The stock of Workday, Inc. (NASDAQ:WDAY) earned “Hold” rating by Jefferies on Wednesday, August 30. Northland Capital maintained the shares of WDAY in report on Thursday, July 27 with “Hold” rating. On Thursday, August 27 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Buy” rating by Canaccord Genuity on Thursday, August 31. As per Wednesday, January 27, the company rating was maintained by Wunderlich. As per Friday, December 2, the company rating was maintained by BMO Capital Markets. Robert W. Baird maintained Workday, Inc. (NASDAQ:WDAY) rating on Thursday, August 25. Robert W. Baird has “Outperform” rating and $95 target.
Since December 19, 2017, it had 0 insider buys, and 34 sales for $261.65 million activity. 75,000 Workday, Inc. (NASDAQ:WDAY) shares with value of $9.54M were sold by BHUSRI ANEEL. On Thursday, March 15 Stankey Michael A. sold $3.41 million worth of Workday, Inc. (NASDAQ:WDAY) or 25,000 shares. The insider Bozzini James sold $545,931. 11,447 shares were sold by Fernandez Gomez Luciano, worth $1.45 million. PEEK MARK S sold $4.74M worth of Workday, Inc. (NASDAQ:WDAY) on Tuesday, December 19. Another trade for 10,000 shares valued at $1.38 million was sold by BATTLE A GEORGE.
Cullen Frost Bankers Inc, which manages about $3.40B US Long portfolio, decreased its stake in Ishares S&P Midcap 400/Value E (IJJ) by 65,628 shares to 23,648 shares, valued at $3.65 million in 2018Q1, according to the filing. It also reduced its holding in Johnson & Johnson Com (NYSE:JNJ) by 7,031 shares in the quarter, leaving it with 190,701 shares, and cut its stake in Powershares Dynamic Lg Cap Val (PWV).
Investors sentiment decreased to 1.25 in Q1 2018. Its down 0.37, from 1.62 in 2017Q4. It worsened, as 30 investors sold WDAY shares while 109 reduced holdings. 70 funds opened positions while 104 raised stakes. 146.97 million shares or 0.81% more from 145.79 million shares in 2017Q4 were reported. 54 are owned by Convergence Inv Prns Limited Liability Corporation. Gulf Bankshares (Uk) accumulated 0.07% or 42,060 shares. Profund Advisors Limited Liability Com invested 0.05% in Workday, Inc. (NASDAQ:WDAY). Eaton Vance Management has 153,765 shares. Guggenheim Limited Liability Co has invested 0.01% in Workday, Inc. (NASDAQ:WDAY). 4,038 are held by Homrich & Berg. Legal & General Gp Public Limited Co reported 537,919 shares. Jasper Ridge Ptnrs Limited Partnership accumulated 0.02% or 3,003 shares. Amundi Pioneer Asset Management Inc has 0.01% invested in Workday, Inc. (NASDAQ:WDAY). Benjamin F Edwards stated it has 0% of its portfolio in Workday, Inc. (NASDAQ:WDAY). Ardevora Asset Llp holds 0.3% or 78,470 shares. Arrowstreet Cap Partnership has 120,800 shares. Pictet North America Advsrs Sa invested in 1.74% or 91,000 shares. Loring Wolcott And Coolidge Fiduciary Advsr Llp Ma owns 200 shares. California State Teachers Retirement holds 216,054 shares.